Soyoung Park

VU Venture Partners is a multi-stage venture capital fund focusing on Consumer, Enterprise, FinTech, Frontier, Healthcare, and PropTech

VU Venture Partners is a multi-stage venture capital fund focusing on Consumer, Enterprise, FinTech, Frontier, Healthcare, and PropTech

HealthTech Capital is a group of private investors dedicated to funding and mentoring new “HealthTech” start ups at the intersection of healthcare and the computer/consumer electronic world. Our goal is to invest and mentor capital efficient companies that use new scalable business model to improve the efficiency of healthcare delivery from the hospital to the home. HealthTech is now an exploding healthcare market that leverages information technologies to decrease healthcare cost. Historically, venture funding has focused on “Efficacy” (therapeutics drugs and medical devices) and paid little attention to improving “Efficiencies” of healthcare delivery. Today, new paradigm shifting companies like Google, Microsoft, Intel, Apple, Amazon and others are turning their attention to HealthTech. HealthTech supports patient-centric healthcare and is distinct from Healthcare IT, enterprise backbone legacy information systems that are well served by existing major players. Our goal is to invest in capital efficient companies that use new business models to improve the efficiency of healthcare delivery.

At 1004 Venture Partners, our mission is to transform the landscape of healthy aging investment. We specialize in identifying and nurturing cutting-edge, transformative technologies. Recognizing the challenges faced by entrepreneurs in early-stage startups, we are dedicated to providing the essential funding and resources needed for growth and success. Our team of experts, with extensive experience in the Life Sciences and investment sectors, offers unparalleled support and guidance to our founders. Join us on our journey to revolutionize the future of healthy aging.

Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. As a leader in muscle biology and the mechanics of muscle performance, we are developing small molecule drug candidates specifically engineered to impact muscle function and contractility. Proud to be a San Francisco Business Times Best Place to Work in 2021 and 2022, a Great Place to Work-Certified company in 2022 and a part of Fortunes Best Workplaces in the Bay Area in 2022 and Fortunes Best Workplaces in BioPharma in 2022.